RxDoctor Payments Data

Rachel Sanes

Family · Hendersonville, TNNPI 1285052407

Payments from drug & device makers

$707in general payments, 2019–2025

Across 34 payments — averaging $20.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$375
  • Lilly USA, LLC$162
  • AbbVie$67
  • Supernus Pharmaceuticals, Inc.$28
  • Bausch Health US, LLC$21
  • Boehringer Ingelheim$19
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$707100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$707 in reported general payments places this provider in the 55th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$62,226
Medicare patients
181
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$83,452
JardianceEmpagliflozin41$44,081
MounjaroTirzepatide28$30,489
TrulicityDulaglutide20$26,927
JanuviaSitagliptin Phosphate21$24,886
Breo ElliptaFluticasone/Vilanterol13$5,966
Atorvastatin Calcium145$1,798
Losartan Potassium132$1,613
Levothyroxine Sodium148$1,312
Rosuvastatin Calcium90$1,151
Esomeprazole Magnesium21$1,085
Ibandronate Sodium11$931
Omeprazole80$910
Duloxetine Hcl39$909
Buspirone Hcl41$866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$375$83,45270 claims
Lilly USA, LLCMounjaro, Trulicity$162$57,41648 claims
Boehringer IngelheimJardiance$19$44,08141 claims
MerckJanuvia$17$24,88621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,706 family providers in Tennessee.

Other family in Hendersonville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →